Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
Tracy L RoseMichael R HarrisonAllision M DealSundhar RamalingamYoung E WhangBlaine BrowerMary DunnChelsea K OstermanHillary M HeilingMarc A BjurlinAngela B SmithMatthew E NielsenHung-Jui TanEric WallenMichael E WoodsDaniel J GeorgeTian ZhangAnthony DrierWilliam Y KimMatthew I MilowskyPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Neoadjuvant gemcitabine and cisplatin plus pembrolizumab met its primary end point for improved pathologic downstaging and was generally safe. A global study of perioperative chemotherapy plus pembrolizumab or placebo is ongoing.